Coincidently, a recent clinical trial showed an absolute advantage in alleviating BPH when adopting a combination therapy with a COX2 inhibitor and FIN [46], which further supports our hypothesis. The gene discussed is PTGS2; the disease is benign prostatic hyperplasia.